Get all your news in one place.
100's of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Japan approves rheumatoid drug Baricitinib for COVID-19 patients

Japan's health ministry approved on Friday the use of rheumatoid arthritis drug Baricitinib for COVID-19 patients, the third such approval following the drugs remdesivir and dexamethasone.

Eli Lilly & Co's Japan subsidiary had applied to regulators for the new use of the drug in December.

(Reporting by Rocky Swift; Editing by Clarence Fernandez)

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.